Patent: 11,654,157
Summary for Patent: 11,654,157
| Title: | Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation |
| Abstract: | Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent. |
| Inventor(s): | Scott Grindrod, Mira Jung, Olga Timofeeva, Milton Brown, Anatoly Dritschilo |
| Assignee: | Shuttle Pharmaceuticals Inc |
| Application Number: | US16/475,999 |
| Patent Claims: | see list of patent claims |
Details for Patent 11,654,157
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Modernatx, Inc. | SPIKEVAX | covid-19 vaccine, mrna | Injection | 125752 | January 31, 2022 | ⤷ Start Trial | 2038-01-09 |
| Modernatx, Inc. | SPIKEVAX | covid-19 vaccine, mrna | Injection | 125752 | September 11, 2023 | ⤷ Start Trial | 2038-01-09 |
| Modernatx, Inc. | SPIKEVAX | covid-19 vaccine, mrna | Injection | 125752 | July 9, 2025 | ⤷ Start Trial | 2038-01-09 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 11,654,157
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 3049251 | ⤷ Start Trial |
| European Patent Office | 3565557 | ⤷ Start Trial |
| United States of America | 12357650 | ⤷ Start Trial |
| United States of America | 2019343859 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
